Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19068587 | 0.86 | HTT (0.54) | SMN1; SMN2POLBALDH1A1KDM4ESLC6A3 | |
| SCHEMBL1280991 | 0.85 | POLB (0.64) | SMN1; SMN2POLBL3MBTL1GLAALDH1A1 | |
| SCHEMBL23868441 | 0.85 | ALDH1A1 (0.49) | SMN1; SMN2POLBALDH1A1KDM4EHPGD | |
| SCHEMBL21543727 | 0.84 | HCRTR1 (0.51) | SMN1; SMN2L3MBTL1GLAALDH1A1KDM4E | |
| SCHEMBL18493737 | 0.82 | HSD17B10 (0.48) | SMN1; SMN2POLBALDH1A1KDM4EHPGD | |
| SCHEMBL1097551 | 0.82 | SGMS2 (0.54) | SMN1; SMN2L3MBTL1ALDH1A1KDM4EHPGD | |
| SCHEMBL20919582 | 0.81 | DDB1 (0.42) | SMN1; SMN2POLBALDH1A1HPGDSLC6A3 | |
| SCHEMBL30211189 | 0.81 | DDB1 (0.42) | SMN1; SMN2POLBALDH1A1HPGDSLC6A3 | |
| SCHEMBL21543887 | 0.81 | ALDH1A1 (0.46) | SMN1; SMN2GLAALDH1A1KDM4EHPGD | |
| SCHEMBL9774310 | 0.80 | POLB (0.57) | SMN1; SMN2POLBL3MBTL1GLAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505560-B2 | Heterobifunctional compounds with improved specificity | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| EP-3676268-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITYFOR THE BROMODOMAIN OF BRD4 | Dana-Farber Cancer Institute, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019079701-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITYFOR THE BROMODOMAIN OF BRD4 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019079701-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITYFOR THE BROMODOMAIN OF BRD4 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | MDM2, STUB1, UBE3C | SMN1; SMN2 2871/4885POLB 3290/4885L3MBTL1 744/4885 |
| US-11505560-B2 | Heterobifunctional compounds with improved specificity | MDM2, STUB1, UBE3C | SMN1; SMN2 2871/4885POLB 3290/4885L3MBTL1 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.